Galimedix Therapeutics announces new pre-clinical data with GAL-201 in an Alzheimer’s disease transgenic model to be presented at AD/PD™ 2024 Conference
You are currently viewing a placeholder content from Elfsight. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
